PHVS

Pharvaris (PHVS)

About Pharvaris (PHVS)

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.

Details

Daily high
$35.77
Daily low
$34.45
Price at open
$35.00
52 Week High
$36.60
52 Week Low
$19.56
Market cap
2.4B
Dividend yield
0.00%
Volume
696,389
Avg. volume
334,207
P/E ratio
-10.85

Pharvaris News

Details

Daily high
$35.77
Daily low
$34.45
Price at open
$35.00
52 Week High
$36.60
52 Week Low
$19.56
Market cap
2.4B
Dividend yield
0.00%
Volume
696,389
Avg. volume
334,207
P/E ratio
-10.85